Stem Cell Therapy Market

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

Report Code: BT 5049 Sep, 2022, by marketsandmarkets.com

[166 Pages Report] The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period. Market growth is driven mainly by factors such as robust funding for stem cell research, increase in the number of cell therapy production facilities that have GMP certification, and growth in the number of clinical trials associated with stem cell therapies. The surge in expanding number of clinical trials is further triggered by the COVID-19 pandemic, with a vast number of clinical trials studying the potential of stem cell therapies in the treatment of SARS-CoV-2 infection.

Stem Cell Therapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Stem Cell Therapy Market Dynamics

DRIVER: Availability of funding for stem cell research

Stem cell research funding has strengthened in the past few years attributed to the need for novel therapeutic interventions in patients with cardiovascular, neurological, and autoimmune disorders. The NIH funding for stem cell research reached its highest peak in 2018 and has shown a year-on-year growth of more than 5% in the stem cell research funding each year. This trend is expected continue with the increase in funding initiatives announced in 2021 For instance, in September 2021, the California Institute for Regenerative Medicine granted a funding of USD 31 million to Stanford research for launching first-in-human trials of stem cells in the treatment of heart failure, stroke, spinal cord tumor.

RESTRAINTS: Ethical concerns related to embryonic stem cells

Studies exploring the therapeutic potential of embryonic stem cells (ESC) are associated with various ethical issues attributed to the destruction of human embryo. Lack of proper federal policies that define what can be funded in the embryo-based stem cell research or therapy development may restrain the market expansion in future to a certain extent. In addition, complexities of regulations in this area require federal guidelines that can support researchers, scientists, and pharmaceutical companies to develop ESC therapy and further facilitate its commercialization.

The allogeneic stem cell therapy accounted for the largest share of the stem cell therapy market in 2021

The stem cell therapy market is segmented into allogeneic and autologous stem cell therapies based on type. In 2021, the allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Comparatively less complications associated with the development and manufacturing of allogeneic stem cell therapies is the key attributive reason to their largest share in the market. This has also led to an increase in the number of clinical trials regarding the development of allogeneic stem cell therapies, making it the fastest growing segment during the forecast period.

The adipose tissue-derived stem cell segment dominated the stem cell therapy market in 2021.

Based on cell source, the stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), placental/umbilical cord-derived MSCs, bone marrow-derived MSCs, and other sources. In 2021, the adipose tissue-derived stem cells segment dominated the stem cell therapy with the highest revenue share, attributed to the growing adoption of these MSCs across different therapeutic indications. Their adoption is propelled by associated advantages such as simple isolation procedures, minimally invasive methods used to ease the harvesting procedure, and comparatively better capacity of proliferation.

In 2021, the musculoskeletal disorders segment has generated highest revenue in the stem cell therapy market.

Based on therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, cardiovascular diseases, wounds and injuries, neurological disorders, surgeries, inflammatory & autoimmune diseases, and other therapeutic applications. The musculoskeletal disorders therapeutic application segment generated highest revenue in 2021. High prevalence of musculoskeletal disorders such as osteoarthritis along with growing demand for regenerative medicine in orthopedic and sports medicine applications is the key contributing factor to the revenue of this share.

North America was the largest regional market for stem cell therapy in 2021.

Geographically, the stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW (Rest of the World). The stem cell therapy market is dominated by the North America region in 2021 and this dominance is anticipated to continue throughout the forecast period. US has emerged as the key revenue contributor to this region, with a robust public-private funding to develop novel stem cell therapy products.

Stem Cell Therapy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Prominent players in the stem cell therapy market include Smith+Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen.Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Inc. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Cell Source, Type, Therapeutic Application and Region

Geographies covered

North America, Europe, Asia Pacific, Rest of the World

Companies covered

Smith+Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Co., Ltd. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India). Athersys (US), Mesoblast Ltd (Australia), Biorestorative Therapies, Inc. (US), Pluristem Inc. (Israel), Brainstorm Cell Limited. (US), ViaCyte, Inc. (US), Gamida Cell (US), Kangstem Biotech (South Korea), Hope Biosciences (US), Cellular Biomedicine Group (US), and Personalized Stem Cells (US)

This report categorizes the stem cell therapy market into the following segments:

Stem Cell Therapy Market, by Type

  • Allogeneic Stem Cell Therapy
  • Autologous Stem Cell Therapy

Stem Cell Therapy Market, by Cell Source

  • Adipose tissue-derived MSCs (mesenchymal stem cells),
  • Bone marrow-derived MSCs,
  • Placental/umbilical cord-derived MSCs, and
  • Other Cell Sources

Stem Cell Therapy  Market, by Therapeutic Application

  • Musculoskeletal Disorders
  • Wounds & Injuries
  • Cardiovascular Diseases
  •  Surgeries
  • Inflammatory & Autoimmune Diseases
  • Neurological Disorders
  • Other Therapeutic Applications

Stem Cell Therapy Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)

Recent Developments

  • In July 2022, CORESTEM (South Korea) continued enrolling participants for the Phase 3 clinical trial of NeuroNata-R. This therapy has received conditional approval for treating ALS patients in South Korea
  • In September 2020, Stemedica Cell Technologies received investigational new drug (IND) approval from the US FDA for intravenous allogeneic mesenchymal stem cells (MSCs) to treat moderate to severe COVID-19.
  • In August 2020, Pluristem Israel) collaborated with Abu Dhabi Stem Cells Center (UAE) to develop stem cell therapies for COVID-19 treatment.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE
          FIGURE 1 STEM CELL THERAPY MARKET
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 30)
    2.1 RESEARCH APPROACH
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET
    2.2 MARKET SIZE ESTIMATION
          FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
          FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
    2.3 GROWTH FORECAST
          FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027)
          FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
          FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 DATA TRIANGULATION
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 PRIMARY INSIGHTS
          FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.6 RESEARCH ASSUMPTIONS
    2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2022 VS. 2026 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET

4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 STEM CELL THERAPY MARKET OVERVIEW
          FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
          FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021
    4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
          FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 48)
    5.1 INTRODUCTION
          FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Availability of funding for stem cell research
                                TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD)
                                FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS
                                TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
                    5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities
                                TABLE 3 NEW GMP FACILITIES, 2017-2020
                    5.2.1.3 Increasing clinical trials for stem cell-based therapies
                                FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020)
                                FIGURE 22 CLINICAL TRIALS, BY PHASE
           5.2.2 RESTRAINTS
                    5.2.2.1 Ethical concerns related to embryonic stem cells
                    5.2.2.2 High cost of cell-based research
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emergence of iPSCs as an alternative to ESCs
                    5.2.3.2 Growing demand for cell & gene therapies
           5.2.4 CHALLENGES
                    5.2.4.1 Technical limitations associated with manufacturing processes
    5.3 TECHNOLOGY ANALYSIS
          TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
    5.4 VALUE CHAIN ANALYSIS
          FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
    5.5 ROLE IN ECOSYSTEM
          FIGURE 24 ECOSYSTEM MARKET MAP
    5.6 SUPPLY CHAIN ANALYSIS
          FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
          TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS
          TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS
    5.7 PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF SUPPLIERS
           5.7.4 BARGAINING POWER OF BUYERS
           5.7.5 INTENSITY OF COMPETITION RIVALRY
    5.8 REGULATORY LANDSCAPE
           5.8.1 NORTH AMERICA
                    TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
           5.8.2 EUROPE
                    TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
           5.8.3 ASIA PACIFIC
                    TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
           5.8.4 REST OF THE WORLD
                    TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
    5.9 PRICING ANALYSIS
           5.9.1 PRICING ANALYSIS
                    TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS
           5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT
    5.10 PATENT ANALYSIS
           FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020)
    5.11 KEY CONFERENCES & EVENTS IN 2022–2023
           5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023)
                      TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023)
    5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
           FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET
           FIGURE 28 KEY BUYING CRITERIA FOR END USERS
           FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES

6 STEM CELL THERAPY MARKET, BY TYPE (Page No. - 70)
    6.1 INTRODUCTION
          TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 ALLOGENEIC STEM CELL THERAPY
           6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT
                    TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 AUTOLOGOUS STEM CELL THERAPY
           6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT
                    TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 STEM CELL THERAPY MARKET, BY CELL SOURCE (Page No. - 75)
    7.1 INTRODUCTION
                              TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
    7.2 ADIPOSE TISSUE-DERIVED MSCS
           7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET
          TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 BONE MARROW-DERIVED MSCS
           7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
                    TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
           7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET
                    TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 OTHER CELL SOURCES
          TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)

8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION (Page No. - 84)
    8.1 INTRODUCTION
          TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
    8.2 MUSCULOSKELETAL DISORDERS
           8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
                    TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 WOUNDS & INJURIES
           8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH
                    TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
           8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH
                    TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 SURGERIES
           8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
                    TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 CARDIOVASCULAR DISEASES
           8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH
                    TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.7 NEUROLOGICAL DISORDERS
           8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH
                    TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.8 OTHER THERAPEUTIC APPLICATIONS
          TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 STEM CELL THERAPY MARKET, BY REGION (Page No. - 98)
    9.1 INTRODUCTION
          TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
          TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
          TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Rising approvals for stem cell therapy products to drive market
                                FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021)
                                TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market
                                TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
    9.3 EUROPE
          TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
          TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market
                                TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Rising adoption of cell-based therapies to drive market
                                TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products
                                TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.3.4 REST OF EUROPE
                    TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                    TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
          FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
          TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
          TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market
                                TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.4.2 SOUTH KOREA
                    9.4.2.1 Favorable government support for stem cell therapy products to support market growth
                                TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Rising cases of neurodegenerative disorders drive market
                                TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                                TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
                    TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
    9.5 REST OF THE WORLD
          TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
          TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 122)
     10.1 INTRODUCTION
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
             FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED
     10.3 REVENUE SHARE ANALYSIS
     10.4 MARKET SHARE ANALYSIS (2021)
     10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                       FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021)
     10.6 COMPETITIVE BENCHMARKING
             10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES
                       TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES
             10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES)
                       TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES]
     10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
             10.7.1 PROGRESSIVE COMPANIES
             10.7.2 STARTING BLOCKS
             10.7.3 RESPONSIVE COMPANIES
             10.7.4 DYNAMIC COMPANIES
                       FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021)
     10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS
             TABLE 115 COMPANY PRODUCT FOOTPRINT
     10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS
             TABLE 116 COMPANY REGIONAL FOOTPRINT
     10.10 COMPETITIVE SCENARIO
             TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS
             TABLE 118 STEM CELL THERAPY MARKET: DEALS

11 COMPANY PROFILES (Page No. - 135)
     11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             11.1.1 SMITH+NEPHEW
                        TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW
                        FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021)
                        TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS
                        TABLE 121 SMITH+NEPHEW: DEALS
             11.1.2 MEDIPOST CO., LTD.
                        TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW
                        FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019)
                        TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS
                        TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS
                        TABLE 125 MEDIPOST CO., LTD: DEALS
                        TABLE 126 MEDIPOST CO., LTD: OTHERS
                        TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS
             11.1.3 JCR PHARMACEUTICALS CO., LTD.
                        TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW
                        FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021)
                        TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS
             11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
                        FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)
                        TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS
                        TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS
                        TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS
             11.1.5 ANTEROGEN. CO., LTD.
                        TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW
                        TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS
             11.1.6 CORESTEM
                        TABLE 136 CORESTEM: BUSINESS OVERVIEW
                        TABLE 137 CORESTEM: PRODUCT OFFERINGS
                        TABLE 138 CORESTEM: REGULATORY APPROVALS
             11.1.7 PHARMICELL CO., LTD.
                        TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW
                        TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS
                        TABLE 141 PHARMICELL CO., LTD.: DEALS
             11.1.8 NUVASIVE, INC.
                        TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW
                        FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021)
                        TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS
             11.1.9 RTI SURGICAL
                        TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW
                        TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS
             11.1.10 ALLOSOURCE
                        TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW
                        TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS
             11.1.11 HOLOSTEM TERAPIE AVANZATE SRL
                        TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW
                        TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS
             11.1.12 ORTHOFIX
                        TABLE 150 ORTHOFIX: BUSINESS OVERVIEW
                        FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021)
                        TABLE 151 ORTHOFIX: PRODUCT OFFERINGS
             11.1.13 STEMPEUTICS RESEARCH
                        TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW
                        TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS
             11.1.14 REGROW BIOSCIENCES PVT LTD.
                        TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW
                        TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS
     11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE)
             11.2.1 ATHERSYS, INC.
             11.2.2 MESOBLAST LTD
             11.2.3 BIORESTORATIVE THERAPIES, INC.
             11.2.4 PLURISTEM INC.
             11.2.5 BRAINSTORM CELL LIMITED.
             11.2.6 GAMIDA CELL
             11.2.7 VIACYTE, INC.
             11.2.8 KANGSTEM BIOTECH
             11.2.9 HOPE BIOSCIENCES
             11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG)
             11.2.11 PERSONALIZED STEM CELLS

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 161)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 CUSTOMIZATION OPTIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the stem cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the stem cell therapy market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include publications from government sources World Health Organization, Organisation for Economic Co-operation and Development, The World Bank, US Census Bureau, International Society for Stem Cell Research (US), National Stem Cell Foundation (US), International Society for Cellular Therapy (ISCT), EuroStemCell, European Society of Gene and Cell Therapy, German Stem Cell Network, Japan Human Cell Society, Chinese Stem Cell Foundation, Brazilian Association of Cell Therapy, Alliance for Regenerative Medicine (ARM)]. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Stem Cell Therapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the stem cell therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the stem cell therapy business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the stem cell therapy market based on type, cell source, therapeutic application and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities and trends)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall stem cell therapy market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Rest of the World
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the stem cell therapy market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Stem Cell Therapy Market Size,  Share & Growth Report
Report Code
BT 5049
Published ON
Sep, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status